1-环戊基-3-吡咯烷醇 | 99065-08-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-环戊基-3-吡咯烷醇
• 英文名称: 1-cyclopentylpyrrolidin-3-ol
• CAS: 99065-08-4
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: BGHMBQDVMFINMV-UHFFFAOYSA-N

物化性质

• 沸点：
  254.0±23.0 °C(Predicted)
• 密度：
  1.115±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-环戊基-3-吡咯烷醇 在 草酰氯 、 三乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 1-cyclopentylpyrrolidine-3-one
  参考文献：
  名称：

  Identification of a novel class of succinyl-nitrile-based Cathepsin S inhibitors

  摘要：

  The synthesis and in vitro activities of a series of suceinyl-nitrile-based inhibitors of Cathepsin S are described. Several members of this class show nanomolar inhibition of the target enzyme as well as cellular potency. The inhibitors displaying the greatest potency contain N-alkyl substituted piperidine and pyrrolidine rings spiro-fused to the alpha-carbon of the P1 residue. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.046
• 作为产物：
  描述：

  1,4-二溴-2-丁醇 、 环戊胺 生成 1-环戊基-3-吡咯烷醇
  参考文献：
  名称：

  Lunsford et al., Journal of medicinal and pharmaceutical chemistry, 1959, vol. 1, p. 73,78,80,81

  摘要：

  DOI：

文献信息

• Pteridinone derivatives as PI3-kinases inhibitors
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：EP1953163A1

  公开（公告）日：2008-08-06

  New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.

  根据其作为PI3-激酶调节剂的药理活性，提供了公式1的新化合物，可用于治疗炎症或过敏性疾病的治疗领域。 这些例子包括炎症和过敏性呼吸道疾病，胃肠道和运动器官的炎症性疾病，炎症性和过敏性皮肤疾病，炎症性眼病，鼻黏膜疾病，涉及自身免疫反应或肾脏炎症的炎症性或过敏性疾病。
• [EN] TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS<br/>[FR] TÉTRAHYDRONAPHTHYRIDINES ET SES DÉRIVÉS AZA À TITRE D'ANTAGONISTES DES RÉCEPTEURS D'HISTAMINE H3
  申请人：EVOTEC NEUROSCIENCES GMBH

  公开号：WO2009121812A1

  公开（公告）日：2009-10-08

  The invention relates to compounds of formula (I), wherein X1a, X1 to X5, Ra, Rb, n and R have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  该发明涉及式(I)的化合物，其中X1a，X1至X5，Ra，Rb，n和R的含义如描述和权利要求中所述。所述化合物可用作组胺H3受体拮抗剂。该发明还涉及药物组合物，以及制备此类化合物的方法，以及作为药物的生产和使用。
• Penem derivatives and antimicrobial agents containing the same
  申请人：SUNTORY LIMITED

  公开号：EP0774465A1

  公开（公告）日：1997-05-21

  Penem derivatives represented by the following Formula (I): wherein Z represents a hydroxyl group or a fluorine atom, R1 represents a substituted or unsubstituted alkyl, alkenyl, aralkyl group, aryl group, heterocyclic, or acyl group, or a hydrogen atom, and R2 represents a hydrogen atom or a carboxyl-protecting group; and pharmacologically acceptable salts thereof are antibacterial agents effective against, inter alia, methicillin-resistant Staphylococcus aureus. The derivatives and salts are novel except when R1 is ethyl and Z is hydroxyl. The analogous compounds in which R2 is a carboxyl-protecting group and any hydroxyl group represented by Z is protected are novel process intermediates.

  Penem衍生物由以下公式（I）表示：其中Z代表一个羟基团或氟原子，R1代表一个取代或未取代的烷基，烯基，芳基甲基，芳基，杂环基或酰基，或氢原子，R2代表一个氢原子或羧基保护基；及其药理学上可接受的盐是有效的抗菌剂，可用于治疗耐甲氧西林金黄色葡萄球菌等感染。这些衍生物和盐是新颖的，除非R1是乙基且Z是羟基。其中R2是羧基保护基且Z代表的任何羟基被保护的类似化合物是新颖的工艺中间体。
• Synthesis, Structure–Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication
  作者：Dorothée Bardiot、Laura Vangeel、Mohamed Koukni、Philippe Arzel、Marleen Zwaagstra、Heyrhyoung Lyoo、Patrick Wanningen、Shamshad Ahmad、Linlin Zhang、Xinyuanyuan Sun、Adrien Delpal、Cecilia Eydoux、Jean-Claude Guillemot、Eveline Lescrinier、Hugo Klaassen、Pieter Leyssen、Dirk Jochmans、Karolien Castermans、Rolf Hilgenfeld、Colin Robinson、Etienne Decroly、Bruno Canard、Eric J. Snijder、Martijn J. van Hemert、Frank van Kuppeveld、Patrick Chaltin、Johan Neyts、Steven De Jonghe、Arnaud Marchand

  DOI：10.3390/molecules27031052

  日期：——

  compound library against SARS-CoV-2, yielding a 1-heteroaryl-2-alkoxyphenyl analog as a promising hit. Antiviral profiling revealed this compound was active against various beta-coronaviruses and preliminary mode-of-action experiments demonstrated that it interfered with viral entry. A systematic structure–activity relationship (SAR) study demonstrated that a 3- or 4-pyridyl moiety on the oxadiazole moiety

  严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 是 COVID-19 的病原体，已导致大流行，这仍然是一个巨大的公共卫生负担。尽管有疫苗可用，但仍然需要小分子抗病毒药物。为了确定可用于随后的命中到先导优化活动的新型和类似药物的命中物质，我们对 160 K 化合物库针对 SARS-CoV-2 进行了高通量筛选，产生了 1-杂芳基-2-烷氧基苯基类似物是一个很有前途的目标。抗病毒分析显示该化合物对各种β-冠状病毒具有活性，初步作用模式实验表明它干扰了病毒进入。系统的构效关系 (SAR) 研究表明，恶二唑部分上的 3-或 4-吡啶基部分是最佳的，而恶二唑可以被各种其他杂芳环取代。此外，烷氧基允许一些结构多样性。
• Methods of reducing risk of infection from pathogens
  申请人：Johnson R. Michael

  公开号：US20050090505A1

  公开（公告）日：2005-04-28

  Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided comprising administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed to one or more airborne pathogens, either from natural sources or from intentional release of pathogens into the environment.

  提供了预防性治疗方法，以保护个人和/或人群免受空气传播病原体的感染。特别是，提供了预防性治疗方法，包括向处于接触或已经接触到一个或多个空气传播病原体的风险人群中的一个或多个成员，从自然来源或故意释放病原体进入环境中，给予钠通道阻滞剂或其药学上可接受的盐。